19:29 , Jul 14, 2017 |  BC Week In Review  |  Company News

Alcyone and Pfizer to build delivery platform for orphan and rare neurological disorders

Alcyone Lifesciences Inc. (Lowell, Mass.) and Pfizer Inc. (NYSE:PFE) partnered to evaluate Alcyone's Pulsar auto-intrathecal injector technology in combination with the pharma's recombinant adeno-associated viral vector (rAAv) gene therapy technology. The companies hope to develop...
08:00 , Feb 29, 2016 |  BioCentury  |  Product Development

Infectious enthusiasm

After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Alcyone Lifesciences, Lysogene deal

Lysogene and Alcyone partnered to evaluate the intraparenchymal delivery of Lysogene’s recombinant adeno-associated virus (rAAV) to treat patients with mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo type A syndrome) using Alcyone’s MEMS Cannula (AMC) targeted delivery...